Added to YB: 2024-11-14
Pitch date: 2024-09-29
SAVA [bearish]
Cassava Sciences, Inc.
+91.57%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Market Cap
$206.6M
Pitch Price
$28.60
Price Target
3.00 (+28%)
Dividend
N/A
Sector
Pharmaceuticals
Category
special_situation
Show full summary:
Cassava Sciences, Inc. - $SAVA
SAVA short: Phase 3 RETHINK-ALZ results due year-end. DOJ indicted collaborator for fraud, SEC fined company $40M for misleading investors. CEO/SVP resigned. No other assets. Expect stock to trade below $3 if trial fails. Cult-like retail base vs no healthcare hedge fund ownership. 804-patient trial across 88 sites.
Read full article (3 min)